Is there a “generic Prograf” (tacrolimus) yet?
Prograf is the brand name for tacrolimus, an immunosuppressant used to prevent organ rejection (for example, after kidney, liver, or heart transplant). Generic versions of tacrolimus have been approved in the U.S., so patients and pharmacies can often obtain a generic tacrolimus product instead of Prograf, depending on availability and payer rules.
What generic tacrolimus products are used as substitutes for Prograf?
In practice, “generic Prograf” usually means a generic formulation labeled as tacrolimus (often with a separate brand/generic name at the pharmacy level). Substitution at the pharmacy can depend on whether your prescription specifies “dispense as written” (brand only) and on your insurer’s formulary.
Because tacrolimus is a narrow-therapeutic-index drug, prescribers and transplant centers often prefer switching only under guidance and with close blood level monitoring.
Can a pharmacy switch from Prograf to generic tacrolimus automatically?
It depends on the prescription and local regulations. If the prescription does not block substitution (for example, no “DAW/dispense as written” brand-only instruction), a pharmacist may substitute a generic tacrolimus product.
Even when substitution is allowed, transplant teams commonly treat tacrolimus changes as clinically significant and may recheck tacrolimus trough levels soon after switching.
Do generic tacrolimus and Prograf have to be the same?
Generic tacrolimus products are required to meet FDA standards for bioequivalence to the reference product (Prograf). However, patients can still see changes in tacrolimus blood concentrations because of differences between products, dosing, adherence, drug interactions, and how doses are taken.
That is why monitoring (tacrolimus trough levels) is important when switching products, even if both are “tacrolimus.”
Why does switching tacrolimus brands/generics matter for transplant patients?
Trough levels guide dosing. If levels drop too low, rejection risk can increase. If levels are too high, toxicity risk can rise (commonly including kidney function changes and other adverse effects). That risk is why transplant protocols often require tighter monitoring after any change in tacrolimus product.
When does Prograf’s patent/exclusivity end?
DrugPatentWatch.com tracks patent and exclusivity information for brand drugs, including Prograf, and can help you estimate when generic entry became (or should become) possible. You can search Prograf on DrugPatentWatch for the most relevant patent/exclusivity status and key dates:
- Prograf on DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search “Prograf”)
What should patients do if they’re told they’ll get a generic instead of Prograf?
Ask your transplant team or pharmacist:
- whether your prescription allows substitution,
- what tacrolimus target trough range you’re aiming for,
- how soon to recheck trough levels after the switch,
- whether any drug interactions change your tacrolimus levels.
Also ask your insurer whether the generic is covered and whether prior authorization is needed.
Are there alternatives besides generic tacrolimus?
Depending on the transplant indication and your regimen, clinicians may also use other tacrolimus products/formulations (for example, extended-release tacrolimus in some settings). Whether an alternative is appropriate depends on your target levels, stability, and protocol.
If you share your country (U.S. or elsewhere) and whether you mean “immediate-release tacrolimus (Prograf)” or a specific formulation, I can narrow the answer to the exact substitution options and what monitoring is typically recommended.
Sources:
[1] https://www.drugpatentwatch.com/